Bladder Cancer News

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma (April 16, 2019)

granted accelerated approval to Balversa (erdafitinib) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy,... Continue Reading

Vicinium Represents New Treatment Option for Non- Muscle Invasive Badder Cancer (June 6, 2018)

Today three-month data from the ongoing Phase 3 VISTA Trial of Vicinium for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG) were released. Overall... Continue Reading

U.S. FDA Grants Fast Track Designation to GemRIS™ in Muscle Invasive Bladder Cancer (May 4, 2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has granted Fast Track designation for GemRIS (TAR-200) for the treatment of patients with organ-confined or locally-advanced Muscle Invasive Bladder Cancer who are unfit for curative... Continue Reading

Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer (April 3, 2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin for patients with locally advanced or metastatic urothelial (bladder) cancer who were previously treated with checkpoint... Continue Reading

Keytruda Improves Survival of Advanced Bladder Cancer (February 26, 2018)

CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of a clinical trial presented at the Genitourinary... Continue Reading